RIVAROXABAN PRECISION DOSING STRATEGY FOR REAL-WORLD ATRIAL FIBRILLATION PATIENTS.

被引：0
|
作者：
Powell, J. [1 ]
Konicki, R. [1 ]
Weiner, D. [1 ]
Patterson, J. [1 ]
Gonzalez, D. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-084
引用
收藏
页码：S100 / S101
页数：2
相关论文
共 50 条
  • [21] Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
    Ikeda, Takanori
    Ogawa, Satoshi
    Kitazono, Takanari
    Nakagawara, Jyoji
    Minematsu, Kazuo
    Miyamoto, Susumu
    Murakawa, Yuji
    Iwashiro, Sanghun
    Kidani, Yoko
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Sato, Shoichiro
    Yamanaka, Satoshi
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 48 (04) : 653 - 660
  • [22] Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis
    Weeda, Erin R.
    White, C. Michael
    Peacock, W. Frank
    Coleman, Craig I.
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (06) : 1117 - 1120
  • [23] Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience
    Akhtar, Tauseef
    Fratti, Juan Del Cid
    Mattumpuram, Jishanth
    Fugar, Setri
    Uprety, Alok
    Nwaichi, Chineme
    Torres, Andrea
    Mann, Hashim
    Golzar, Yasmeen
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 320 : 78 - 82
  • [24] Real-world variability in dabigatran levels in patients with atrial fibrillation
    Chan, N. C.
    Coppens, M.
    Hirsh, J.
    Ginsberg, J. S.
    Weitz, J. I.
    Vanassche, T.
    Douketis, J. D.
    Schulman, S.
    Eikelboom, J. W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (03) : 353 - 359
  • [25] Using real-world data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK
    Gibbs, Liza
    Govil, Priya
    Kent, Seamus
    Duffield, Stephen
    Rowark, Shaun
    Sharma, Manuj
    Ali, Ayad
    Patrick, Amanda
    Jaksa, Ashley
    Jonsson, Pall
    Gatto, Nicolle
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 74 - 74
  • [26] Predictors of major bleeding in patients with atrial fibrillation treated with rivaroxaban in XANTUS: findings from a real-world prospective study
    Kirchhof, P.
    Haas, S.
    Amarenco, P.
    Hess, S.
    Kuhls, S.
    Van Eickels, M.
    Turpie, A. G. G.
    Camm, A. J.
    EUROPEAN HEART JOURNAL, 2016, 37 : 512 - 513
  • [27] Incidence of Major Bleeding in a Real-World Population of 57,070 Nonvalvular Atrial Fibrillation Patients Treated With Rivaroxaban
    Peacock, Frank
    Patel, Manesh
    Yuan, Zhong
    Sicignano, Nicholas
    Hopf, Kathleen
    Tamayo, Sally
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2017, 37
  • [28] Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
    Lip, Gregory Y. H.
    Pan, Xianying
    Kamble, Shital
    Kawabata, Hugh
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    PLOS ONE, 2018, 13 (04):
  • [29] NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters?
    Hwang, Jongmin
    Han, Seongwook
    Bae, Han-Joon
    Jun, Seung-Woon
    Choi, Sang-Woong
    Lee, Cheol-Hyun
    Kim, In-Cheol
    Cho, Yun-Kyeong
    Park, Hyoung-Seob
    Yoon, Hyuck-Jun
    Kim, Hyungseop
    Nam, Chang-Wook
    Hur, Seung-Ho
    Lee, Sang-Hoon
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (02) : 306 - 313
  • [30] Population Pharmacokinetics of Rivaroxaban in Real-World Patients
    Alqahtani, Saeed
    Alnahdi, Jamilah
    Almofada, Razan
    bin Hazza, Asma'a
    Alsultan, Abdullah
    Alqahtani, Farjah
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (08): : 943 - 949
12345